

Pharmaceutical Benefits Scheme (PBS) Listings

1 August 2025

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 August 2025**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

High-risk neuroblastoma

Eflornithine (192 mg tablet) (Ifinwil®) is now listed on the PBS for the treatment of high-risk neuroblastoma. Authority applications for initial treatment can be made either in real-time using the Online PBS Authorities system or in writing. Applications for grandfather and continuing treatments can be made either in real-time using the Online PBS Authorities system or by telephone.

Fabry disease

Migalstat (123 mg capsule) (Galafold®) has had a change to the number of repeats from 5 to 6. Authority applications for initial and grandfather treatments can be made in writing. Applications for continuing treatment can be made either in real-time using the Online PBS Authorities system or by telephone.

Uncontrolled severe asthma; uncontrolled severe allergic asthma; severe chronic spontaneous urticaria

Omalizumab (75 mg/0.5 mL injection, 0.5 mL syringe; 150 mg/mL injection, 1 mL syringe) (Omyclo®) is a biosimilar now listed on the PBS for the treatment of uncontrolled severe asthma, uncontrolled severe allergic asthma and severe chronic spontaneous urticaria.

Omalizumab (75 mg/0.5 mL injection, 0.5 mL pen device; 150 mg/mL injection, 1 mL pen device; 300 mg/2 mL injection, 2 mL pen device) (Xolair®) is now listed on the PBS for treatment of uncontrolled severe asthma, uncontrolled severe allergic asthma and severe chronic spontaneous urticaria.

Omalizumab (150 mg/mL injection, 1 mL syringe) (Xolair®) has been delisted.

Severe chronic plaque psoriasis; severe psoriatic arthritis; severe Crohn's disease; complex refractory fistulising Crohn's disease; moderate to severe ulcerative colitis

Ustekinumab (45 mg/0.5 mL injection, 0.5 mL syringe; 90 mg/mL injection, 1 mL syringe; 130 mg/26 mL injection, 26 mL vial) (Steqeyma®) is a biosimilar now listed on the PBS for the treatment of severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn's disease, complex refractory fistulising Crohn's disease and moderate to severe ulcerative colitis.

Stage IIIB, IIIC, IIID or Stage IV malignant melanoma (nivolumab); Stage III or Stage IV malignant melanoma (ipilimumab)

Nivolumab (40 mg/4 mL injection, 4 mL vial; 100 mg/10 mL injection, 10 mL vial) (Opdivo®) and ipilimumab (50 mg/10 mL injection, 10 mL vial; 200 mg/40 mL injection, 40 mL vial) (Yervoy®) have had a change to their restrictions. Authority applications for initial and continuing treatment with nivolumab can be made either in real-time using the Online PBS Authorities system or by telephone. Prescriptions for ipilimumab induction treatment are Authority required (STREAMLINED).

Osteoporosis; giant cell tumour of bone; bone metastases

Denosumab (60 mg/mL injection, 1 mL syringe) (Jubbonti®); (120 mg/1.7 mL injection, 1.7 mL vial) (Wyost®) are biosimilars now listed on the PBS for the treatment of osteoporosis, giant cell tumour of bone and bone metastases. Prescriptions for initial and continuing treatment are Authority required (STREAMLINED).

Advanced, metastatic or recurrent endometrial carcinoma

Durvalumab (120 mg/2.4 mL injection, 2.4 mL vial; 500 mg/10 mL injection, 10 mL vial) (Imfinzi®) is listed on the PBS for the treatment of advanced, metastatic or recurrent endometrial carcinoma. Prescriptions for initial and continuing treatment are Authority required (STREAMLINED).

Advanced Parkinson's disease

Foslevodopa + foscarnidopa (foslevodopa 2.4 g/10 mL + foscarnidopa 120 mg/10 mL injection, 7 x 10 mL vials) (Vyalev®) is now listed on the PBS for the treatment of advanced Parkinson's disease. Prescriptions for treatment are Authority required (STREAMLINED).

Contraception

Drospirenone (drospirenone 4 mg tablet [24] (& inert substance tablet [4], 3x28) (Slinda®) is now listed on the PBS for contraception. It is listed as an unrestricted benefit.

1 August 2025 delisted PBS listings**Glaucoma and ocular hypertension**

Betaxolol (0.5% eye drops, 5 mL) (Betoptic®) has been delisted.

Acute myocardial infarction

Tenecteplase (50 mg injection, 10 mL syringe) (Metalyse®) has been delisted.

Locally advanced or metastatic differentiated thyroid cancer

Cabozantinib (20 mg tablet; 40 mg tablet; 60 mg tablet) (Cabometyx®) no longer has a listing for Grandfather arrangements.

Vision threatening non-infectious uveitis

Adalimumab (20 mg/0.2 mL injection, 0.2 mL syringe; 20 mg/0.4 mL injection, 0.4 mL syringe; 40 mg/0.4 mL injection, 0.4 mL pen device; 40 mg/0.4 mL injection, 0.4 mL syringe; 40 mg/0.8 mL injection, 0.8 mL pen device; 40 mg/0.8 mL injection, 0.8 mL syringe) no longer has a listing for Grandfather arrangements.

Important Information**Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload**

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit servicesaustralia.gov.au/HPOS for more information on how to Link your Health Identifiers to HPOS and Manage delegations.

Reminders

PBS Authorities – written authority application forms

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval.

Correct PBS item code

When prescribing PBS medicines via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.

Ensuring you are providing accurate data

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.

More information

For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.